top of page

Biopharma Daily Stock Updates - 04/13/22

$XBI $90.41 | +3.8%


Covid Updates

$NVAX +7.0% Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine. source

$MNOV +2.4% MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome. source

Pipeline Updates

$INMB +12.2% INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease source

$AMRX +0.9% Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly) source

$MBIO -2.1% Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma. source

$ONCT -0.9% Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma. source

$CCXI +4.7% ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022. source

$LGVN -6.4% Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial. source

$ESPR +7.4% Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology. source

$AMTI +6.2% Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company’s Proprietary Technology Platform. source

$LCTX +5.6% Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer. source

$PRQR -12.6% ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy. source

Business Updates

$AQST +2.8% Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital. source

$HALO -0.4% Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader. source

$SRRA +38.5% GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn. source

$AFMD +5.1% Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares. source

$LQDA -15.2% Liquidia Announces Pricing of Public Offering of Common Stock. source


Posted by FS/JM



bottom of page